CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors - PubMed
7 hours ago
- #CSF1R inhibition
- #immunotherapy
- #triple-negative breast cancer
- Combination of CSF1R inhibitor pexidartinib with eribulin showed clinical benefit in heavily pretreated metastatic TNBC patients, with a 12-week progression-free survival rate of 36%.
- Patients responding to therapy had increased baseline immune activation, including enriched memory T cells and higher PD-1 expression on CD4+ T cells.
- Preclinical studies in transgenic models found that adding CSF1R inhibition to anti-PD-1 therapy boosted efficacy, leading to transient tumor regression and expansion of memory T cells.
- The findings support strategies to improve anti-PD-1 therapy by targeting immunosuppressive macrophages to enhance outcomes in refractory TNBC.